Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025

MYRIAD GENETICS INC

2024-Q3 EPS reported -$0.94 revenue$627,000,000

Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.
GAAP EPS -$0.24 vs -$0.75; adj EPS $0.06 vs -$0.03.
FY2024 guidance raised: revenue $837-843M, adj EPS $0.12-0.14.
UnitedHealthcare to stop covering GeneSight for commercial plans Jan 1, 2025; $10M Q3 / $40M TTM revenue at risk from UNH commercial.
GeneSight revenue +34% YoY to $47.7M; total test volumes +6% to 376K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.